Real-world evidence links higher injection frequency to better VA outcomes and reduced CST fluctuations, reinforcing ...
Prolonged near work in low luminance may accelerate myopia primarily by limiting retinal illumination through sustained accommodative miosis rather than by electronic screens per se.
According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. EYE PCR’s fixOflex is now eligible for European ...
Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, ...
Advanced technology lenses work best in pristine eyes. Problems with ocular alignment, pupil size, ocular surface disease, irregular astigmatism, corneal dystrophies, scarring, and diseases of the ...
The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...
Ophthalmology Times, hosted by Douglas D. Koch, MD, Professor and Allen, Mosbacher, and Law Chair in Ophthalmology at the ...
At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...
More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
A discussion of his situation led to the selection of the enVista Envy IOL. One month postoperatively, the patient achieved ...
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results